Search
In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.
With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.
Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.
Unlike most small cell lung cancer tumors, these retain a normal copy of a protein called RB.
More sugar available for immune cells could mean better immune responses against cancer.
Scientists in all stages of their careers gathered recently to hear from Sharon Milgram speak about how attitudes and behaviors that can get in the way of a successful career.
An FDA-approved drug used to treat leukemia can serve as a temporary off switch for CAR T cells, MSK scientists have found.
Kathryn V. Anderson has been elected a member of the Institute of Medicine of the National Academies.
Two outstanding graduate students from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences (GSK) have been awarded federal funding to pursue promising cancer research.
Investigators have shown how gut microbes promote the formation of a type of immune cell called regulatory T cells.